Computer Optimization of Biodegradable Nanoparticles Fabricated by Dispersion Polymerization

Quality by design (QbD) in the pharmaceutical industry involves designing and developing drug formulations and manufacturing processes which ensure predefined drug product specifications. QbD helps to understand how process and formulation variables affect product characteristics and subsequent optimization of these variables vis-à-vis final specifications. Statistical design of experiments (DoE) identifies important parameters in a pharmaceutical dosage form design followed by optimizing the parameters with respect to certain specifications. DoE establishes in mathematical form the relationships between critical process parameters together with critical material attributes and critical quality attributes. We focused on the fabrication of biodegradable nanoparticles by dispersion polymerization. Aided by a statistical software, d-optimal mixture design was used to vary the components (crosslinker, initiator, stabilizer, and macromonomers) to obtain twenty nanoparticle formulations (PLLA-based nanoparticles) and thirty formulations (poly-ɛ-caprolactone-based nanoparticles). Scheffe polynomial models were generated to predict particle size (nm), zeta potential, and yield (%) as functions of the composition of the formulations. Simultaneous optimizations were carried out on the response variables. Solutions were returned from simultaneous optimization of the response variables for component combinations to (1) minimize nanoparticle size; (2) maximize the surface negative zeta potential; and (3) maximize percent yield to make the nanoparticle fabrication an economic proposition.

• Publication year

  2015

• Venue

  International Journal of Environmental Research and Public Health

• Publication date

  2015-12-22

• Fields of study

  Medicine, Materials Science, Engineering

• Identifiers
  DOI 10.3390/ijerph13010047PMID 26703678PMCID 4730438
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• D-Optimal mixture experimental design for stealth biodegradable crosslinked docetaxel-loaded poly-ε-caprolactone nanoparticles manufactured by dispersion polymerization.

  2015cited by this paper
• Polylactide-based paclitaxel-loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies.

  2014cited by this paper
• Understanding Pharmaceutical Quality by Design

  2014cited by this paper
• Optimization of the fabrication of novel stealth PLA-based nanoparticles by dispersion polymerization using D-optimal mixture design

  2014cited by this paper
• MS-Monitored Conjugation of Poly(ethylene glycol) Monomethacrylate to RGD Peptides.

  2014cited by this paper
• Implementation of mixture design for formulation of albumin containing enteric-coated spray-dried microparticles

  2013cited by this paper
• The Involvement of Girls and Boys with Bullying: An Analysis of Gender Differences

  2013cited by this paper
• Nanostructure-based drug delivery systems for brain targeting

  2012cited by this paper
• Theranostics: combining imaging and therapy.

  2011cited by this paper
• Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation.

  2010influential reference
• Chapter 2:Strategies for Transmembrane Passage of Polymer-based Nanostructures

  2010cited by this paper
• Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control

  2008cited by this paper
• Pharmacokinetics and biodistribution of nanoparticles.

  2008cited by this paper
• A Note on Model Selection in Mixture Experiments

  2007cited by this paper
• The effect of paclitaxel‐loaded nanoparticles with radiation on hypoxic MCF‐7 cells

  2007influential reference
• Optimisation of Natural Ingredient Based Lipstick Formulation by Using Mixture Design

  2007cited by this paper
• Polymeric Nanoparticles as Drug Carriers

  2006cited by this paper
• Polymeric Nanoparticles as Drug Carriers

  2006cited by this paper
• Cancer nanotechnology: opportunities and challenges

  2005cited by this paper
• An example of application of a mixture design with constraints to a pharmaceutical formulation

  2003cited by this paper
• Experiments with Mixtures

  1992cited by this paper
• Experiments with Mixtures

  1992cited by this paper
• NON CLASSICAL EXPERIMENTAL DESIGNS IN PHARMACEUTICAL FORMULATION

  1991cited by this paper

• Dispersion polymerization induced self-assembly (pisa) techniques for the fabrication of polymeric nanoparticles for biomedical applications

  2023cites this paper
• Nanotechnology in the development of small and large molecule tyrosine kinase inhibitors and immunotherapy for the treatment of HER2-positive breast cancer

  2022cites this paper
• Nanopharmaceuticals to target antifilarials: Administration of old age drugs in a novel way

  2021cites this paper
• Fabrication of Paclitaxel and 17AAG-loaded Poly-ε-Caprolactone Nanoparticles for Breast Cancer Treatment.

  2021cites this paper
• Design of Experiments for Critical Material Attributes Assessment of Linagliptin and Metformin Fixed-dose Combination Tablets

  2021cites this paper
• Studies on polyethylene glycol-monoclonal antibody conjugates for fabrication of nanoparticles for biomedical applications

  2020cites this paper
• Computer Optimization of Stealth Biodegradable Polymeric Dual-Loaded Nanoparticles for Cancer Therapy using Central Composite Face-Centered Design.

  2020cites this paper
• Formulation and Optimization of Monolithic Fixed-Dose Combination of Metformin HCl and Glibenclamide Orodispersible Tablets

  2020cites this paper
• Conversion of PLGA nanoparticle suspensions into solid dosage forms via fluid bed granulation and tableting

  2019cites this paper
• Pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, is a synthetic cholesterol-lowering agent that belongs to statin class [1]. Pravastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the cholesterol biosynthesis pathway, which eventually red

  2018cites this paper
• Nanosystem trends in drug delivery using quality‐by‐design concept

  2017cites this paper
• Design of Experiments for Coating Process of Valsartan and Pravastatin Fixed-dose Combination Tablet

  2017cites this paper